Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Icotrokinra - Janssen Biotech

Next Previous
Drug Profile

Icotrokinra - Janssen Biotech

Alternative Names: ICOTYDE; JNJ 77242113; JNJ-2113; PN-21235; PN-235

Latest Information Update: 30 Oct 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Protagonist Therapeutics
  • Developer Janssen Biotech
  • Class Amides; Anti-inflammatories; Antipsoriatics; Antirheumatics; Butyric acids; Disulfides; Ethanolamines; Indoles; Naphthalenes; Pentanoic acids; Peptides; Phenyl ethers; Pyridines; Sulfhydryl compounds
  • Mechanism of Action Interleukin-23 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Plaque psoriasis
  • Registered Erythrodermic psoriasis; Generalised pustular psoriasis
  • Phase III Psoriatic arthritis; Ulcerative colitis
  • Phase II/III Crohn's disease

Most Recent Events

  • 19 Oct 2026 Janssen Cilag plans a phase III trial for Immunological disorders (In neonates, In infants, In children, In adolescents) in Spain, Germany, Poland ,Hungary, Canada, China and Turkey (PO, Tablet) in January 2027 (CTIS2026-526290-41-00)
  • 09 Oct 2026 Efficacy and adverse events data from a phase III ICONIC-LEAD trial in Plaque Psoriasis released by Johnson & Johnson
  • 02 Oct 2026 Efficacy and adverse events data from the phase III ICONIC-TOTAL trial in Plaque Psoriasis released by Johnson & Johnson

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top